Brief Article
Copyright ©2012 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Hepatol. Jan 27, 2012; 4(1): 11-17
Published online Jan 27, 2012. doi: 10.4254/wjh.v4.i1.11
Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis
Nobuhiro Aizawa, Hirayuki Enomoto, Hiroyasu Imanishi, Masaki Saito, Yoshinori Iwata, Hironori Tanaka, Naoto Ikeda, Yoshiyuki Sakai, Tomoyuki Takashima, Takashi Iwai, Ei-ichiro Moriwaki, Soji Shimomura, Hiroko Iijima, Hideji Nakamura, Shuhei Nishiguchi
Nobuhiro Aizawa, Hirayuki Enomoto, Hiroyasu Imanishi, Masaki Saito, Yoshinori Iwata, Hironori Tanaka, Naoto Ikeda, Yoshiyuki Sakai, Tomoyuki Takashima, Takashi Iwai, Ei-ichiro Moriwaki, Soji Shimomura, Hiroko Iijima, Hideji Nakamura, Shuhei Nishiguchi, Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Mukogawa-cho 1-1, Nishinomiya, Hyogo 663-8501, Japan
Hideji Nakamura, Department of Gasteroenterology, Nissay Hospital, Osaka 550-0012, Japan
Author contributions: Aizawa N and Enomoto H contributed equally to this work; Enomoto H and Nakamura H designed and proposed the research; all authors approved the analysis and participated in drafting the article; Aizawa N, Enomoto H, Saito M, Iwata Y, Tanaka H, Ikeda N, Sakai Y, Takashima T, Iwai T, Moriwaki E, Shimomura S and Iijima H treated the patients, performed the liver biopsies and collected the clinical data; all authors were involved in the histological evaluation and the final histopathological results were confirmed by Enomoto H and Imanishi H; Aizawa N, Enomoto H and Nishiguchi S performed the statistical analysis; Enomoto H, Imanishi H and Nakamura H wrote the manuscript; all authors were involved in the manuscript revision and approved the final version of the manuscript.
Supported by A Grant-in-Aid for Health and Labor Sciences Research from the Ministry of Health, Labour and Welfare of Japan
Correspondence to: Hirayuki Enomoto, MD, PhD, Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Mukogawa-cho 1-1, Nishinomiya, Hyogo 663-8501, Japan. enomoto@hyo-med.ac.jp
Telephone: +81-798-456472 Fax: +81-798-456474
Received: March 31, 2011
Revised: September 19, 2011
Accepted: January 15, 2012
Published online: January 27, 2012
Abstract

AIM: To analyze the relationship between the glycated albumin (GA) to glycated hemoglobin (HbA1c) ratio and the histological grading of liver fibrosis.

METHODS: The study retrospectively included consecutive hepatitis C virus positive chronic liver disease patients (n = 142) who had undergone percutaneous liver biopsy between January 2008 and March 2010 at our institution. The ratios of GA/HbA1c were calculated in all patients to investigate the relationship with the degree of the liver fibrosis. The values of the aspartate aminotransferase-to-platelet ratio index (APRI), an excellent marker for the evaluation of liver fibrosis, were also calculated. In addition, we combined the ratio of GA/HbA1c and the APRI in order to improve our ability to detect the presence of significant liver fibrosis.

RESULTS: Sixty-one (43%) patients had either no fibrosis or minimal fibrosis (METAVIR score: F0-F1), while 25 (17%) had intermediate fibrosis (F2). Fifty-six (39%) patients had severe fibrosis (F3-F4) and 27 of them had cirrhosis (F4). The mean values of the GA/HbA1c increased with the progression of the fibrosis (F0-1: 2.83 ± 0.24, F2: 2.85 ± 0.24, F3: 2.92 ± 0.35, F4: 3.14 ± 0.54). There was a significant difference between the F0-F1 vs F4, F2 vs F4, and F3 vs F4 groups (P < 0.01, P < 0.01, P < 0.01 and P < 0.05, respectively). The GA/HbA1c ratio was significantly higher in the patients with cirrhosis (F4) than in those without cirrhosis (F0-F3) (3.14 ± 0.54 vs 2.85 ± 0.28, P < 0.0001). The GA/HbA1c ratio was also significantly higher in the patients with severe fibrosis (F3-F4) than in those without severe liver fibrosis (F0-F2) (3.03 ± 0.41 vs 2.84 ± 0.24, P < 0.001). Furthermore, the GA/HbA1c ratio was also significantly higher in the patients with significant fibrosis (F2-F4) than in those without significant liver fibrosis (F0-F1) (2.98 ± 0.41 vs 2.83 ± 0.24, P < 0.001). The diagnostic performance of the increased GA/HbA1c ratio (> 3.0) was as follows: its sensitivity and specificity for the detection of liver cirrhosis (F4) were 59.3% and 70.4%, respectively and its sensitivity and specificity for the detection of severe liver fibrosis (F3-F4) were 50.0% and 74.4%, respectively. With regard to the detection of significant fibrosis (F2-F4), its sensitivity was 44.4% and its specificity was 77.0%. Although even the excellent marker APRI shows low sensitivity (25.9%) for distinguishing patients with or without significant fibrosis, the combination of the APRI and GA/HbA1c ratio increased the sensitivity up to 42.0%, with only a modest decrease in the specificity (from 90.2% to 83.6%).

CONCLUSION: The GA/HbA1c ratio increased in line with the histological severity of liver fibrosis, thus suggesting that this ratio is useful as a supportive index of liver fibrosis.

Keywords: Glycated albumin; Glycated hemoglobin; Liver fibrosis; Liver biopsy; Hepatitis C virus